Form IT-648

Form IT-648 is the specific New York State tax form used by individuals, partners, and S-corporation shareholders to claim a refundable credit of up to 20% on qualified research expenditures incurred by new life sciences businesses. It serves as the primary mechanism for early-stage biotechnology and pharmaceutical firms to recover capital invested in scientific innovation within the state’s borders.

The New York State Life Sciences Research and Development Tax Credit represents a targeted fiscal instrument designed to bolster the state’s standing as a global hub for biotechnology and biomedical innovation. Established under Tax Law Section 43, the program aims to mitigate the high capital risks associated with early-stage life sciences research. Unlike many other credits that focus on general business expansion, this credit specifically addresses the unique needs of “new” businesses in highly technical scientific fields, offering a liquidity injection through full refundability even when a firm has no tax liability. The administration of the credit is a collaborative effort between two primary state agencies: Empire State Development (ESD) and the New York State Department of Taxation and Finance (DTF). ESD acts as the gatekeeper, responsible for certifying businesses as qualified life sciences companies and issuing the mandatory Certificate of Tax Credit. The DTF oversees the tax filing process, with Form IT-648 serving as the reporting vehicle for taxpayers subject to personal income tax under Article 22.

Legislative Foundation and the Life Science Initiative

The Genesis of Form IT-648 is inextricably linked to the broader New York State Life Science Initiative, a $620 million strategic program launched in 2017 to catalyze the growth of a world-class life science research cluster. The legislature recognized that while New York possessed elite academic research institutions, it often struggled to retain the commercial spin-offs resulting from that research. Consequently, Tax Law Section 43 was enacted to provide a significant, fully refundable tax credit that offsets the costs of conducting research and development within the state. This legislation was designed to complement other economic development programs, such as the Excelsior Jobs Program and the START-UP NY initiative, by providing a niche benefit specifically tailored to the life sciences sector.

Jurisdictional Framework

The program operates under the authority of both the Tax Law and the Economic Development Law. Specifically, Economic Development Law Section 352 provides the foundational definitions for what constitutes a life sciences company, while Tax Law Section 43 dictates the calculation and application of the credit. This dual-agency oversight ensures that the credit is both scientifically valid—vetted by the experts at ESD—and fiscally compliant—audited by the DTF. For the taxpayer, this means that the journey to claiming the credit begins long before the tax return is filed. A company must first undergo a rigorous application process with ESD to receive a certificate of tax credit, which then acts as the “golden ticket” required to complete Form IT-648.

Strategic Objectives of the Credit

The primary objective of the Life Sciences R&D Tax Credit is to encourage new businesses to locate, invent, commercialize, and produce in New York State. By offering a credit that is fully refundable, the state provides an immediate cash benefit to pre-revenue startups that would otherwise have to wait years for profitability to realize any value from traditional non-refundable tax credits. This cash-flow acceleration is critical in the life sciences industry, where the “valley of death”—the period between initial discovery and commercial viability—is exceptionally long and capital-intensive.

Program Metric	Value/Detail
Annual Statewide Allocation	$10 Million
Individual Entity Annual Cap	$500,000
Individual Entity Lifetime Cap	$1.5 Million
Maximum Benefit Period	3 Consecutive Years
Refundability	100% Fully Refundable

Defining the Qualified Life Sciences Company

To access the benefits reported on Form IT-648, an entity must qualify as a “Life Sciences Company” as defined by Economic Development Law Section 352(11). The law defines such a company as a business entity, organization, or institution that devotes the majority of its efforts to various stages of research, development, technology transfer, and commercialization related to life sciences. This definition is purposely broad to capture the evolving nature of the sector but is strictly limited to certain strategic scientific fields.

Eligible Scientific Domains

The scope of “life sciences” under the statute encompasses a wide range of advanced and applied sciences that expand the understanding of human physiology or have the potential to lead to medical advances or therapeutic applications.

• Agricultural Biotechnology: Research into the genetic engineering of plants and microorganisms to improve crop yields or develop bio-based fuels.
• Biopharmaceuticals: The development of medical drugs produced using biotechnology, including vaccines and recombinant proteins.
• Bioinformatics: The use of computer technology to collect, store, analyze, and disseminate biological data and information, such as DNA and amino acid sequences.
• Biomedical Engineering: The application of engineering principles and design concepts to medicine and biology for healthcare purposes.
• Genomics: The branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
• Medical Devices: The design and development of instruments, apparatuses, or machines used in the diagnosis or treatment of disease.
• Medical Nanotechnology: The medical application of nanotechnology, ranging from the use of nanomaterials for drug delivery to the development of “nanobots”.

The New Business Requirement

A critical hurdle for eligibility is that the company must be a “new business.” This is not merely a descriptive term but a legal standard defined under New York State Tax Law Section 210-b(1)(f). To meet this definition, a business must satisfy the following criteria:

1. Direct Ownership Test: The business cannot be more than 50% owned or controlled, either directly or indirectly, by another company that is already a taxpayer in New York State.
2. Operational History: The company must not have been a taxpayer in New York State for more than five years prior to the taxable year in which it first claims the credit.
3. Similarity Test: The business must not be “substantially similar” in ownership and operation to another company that is or was previously a taxpayer in New York.

This requirement ensures that the state’s resources are focused on genuine startups rather than the relocation of subsidiaries or divisions of established corporations. The “substantially similar” test is particularly scrutinized during audits to prevent existing firms from reorganizing simply to “reset” their eligibility for tax incentives.

Qualified Research Expenditures and Local Guidance

The calculation of the credit hinges on the identification of Qualified Research Expenditures (QREs). While New York law leverages the federal definitions found in Internal Revenue Code (IRC) Section 41(b), there are significant state-specific modifications that are detailed in local revenue office guidance, most notably TSB-M-17(1)C.

Inclusions: What Qualifies

To be eligible for the credit, research and development expenditures must be incurred in New York State on or after January 1, 2018. The primary categories of eligible costs include:

• Wages: Payments made to employees for “qualified services” performed in the state. This includes researchers, their direct supervisors, and those directly supporting the research effort. For employees whose time is split between research and administrative duties, companies must maintain rigorous time-tracking records to justify the portion of wages claimed.
• Supplies: Costs for tangible property used in the conduct of qualified research. This excludes land, improvements to real property, and any property subject to depreciation.
• Computer Use Fees: Amounts paid for the right to use computers in the conduct of qualified research. In the modern life sciences landscape, this often extends to cloud computing services used for high-throughput screening or genetic sequencing.

The Critical Exclusion: Contract Research

The most notable divergence from the federal R&D tax credit is New York’s treatment of contract research. While the federal credit typically allows a taxpayer to claim 65% of expenditures paid to third-party contractors for research, the New York Life Sciences R&D credit explicitly excludes all “contract research expenses”.

This exclusion is a deliberate policy choice by the state. The goal of the program is not just to fund scientific discovery, but to build a permanent workforce within New York. By excluding contract research, the state incentivizes firms to hire their own scientists and build their own lab facilities rather than outsourcing the work to CROs (Contract Research Organizations) that might be located in other states or countries. For many “virtual” biotech startups that operate primarily through contractors, this exclusion may render the state credit significantly less valuable than the federal one unless they pivot to an in-house model.

Four-Part Test Integration

Local revenue office guidance clarifies that while the state has its own definitions for things like contract research, the fundamental nature of the research must still meet the federal “four-part test” established under IRC Section 41.

Test	Requirement
Permitted Purpose	The research must relate to a new or improved business component’s function, performance, reliability, or quality.
Elimination of Uncertainty	The activity must be intended to discover information that would eliminate uncertainty regarding the development or improvement of a product or process.
Process of Experimentation	Substantially all of the activities must constitute a process of experimentation involving the evaluation of alternatives through modeling, simulation, or trial and error.
Technological in Nature	The research must fundamentally rely on principles of physical or biological science, engineering, or computer science.

Administrative Guidance and Application Procedures

Claiming the credit via Form IT-648 is a two-step administrative process. Unlike many general business credits that are “self-certified” on a tax return, the Life Sciences R&D credit requires prior approval and certification from Empire State Development.

Step 1: ESD Certification

A business must first complete a Consolidated Funding Application (CFA) or a specific Life Sciences Tax Credit Application and submit it to the ESD regional office. The application is evaluated on a rolling basis, and because of the $10 million statewide annual cap, the date of filing is critical. ESD will verify that the company meets the “new business” criteria and that its activities align with the definition of a life sciences company. Upon approval, ESD issues a Certificate of Tax Credit which specifies the amount of credit allowed and the tax year in which it must be claimed.

Step 2: Department of Taxation and Finance Filing

Once the certificate is in hand, the taxpayer attaches it to Form IT-648 and files it with their annual income tax return. The form is used to report the credit amount from the certificate and, if applicable, allocate that credit among partners or shareholders. Taxpayers subject to Article 9-A (Corporations) use Form CT-648, while all others—individuals, sole proprietors, partners, and S-corp shareholders—use Form IT-648.

TSB-M-17(1)C and Technical Nuances

The New York State Department of Taxation and Finance issued TSB-M-17(1)C to provide clarity on several technical aspects of the credit. One of the most important clarifications concerns the “three consecutive years” rule. The credit is allowed for up to three consecutive tax years during which the qualified life sciences company meets the eligibility criteria. The guidance specifies that subsequent certifications will not extend this three-year limitation. If a company fails to meet the criteria in Year 2, it does not get an “extra” year at the end; the window is fixed at three years from the initial qualification.

Furthermore, the guidance emphasizes that the credit cannot be used to reduce the tax due to less than the fixed dollar minimum tax for corporations. For individuals filing IT-648, however, the credit is fully refundable as an overpayment of tax.

Analyzing Form IT-648 Structure and Schedules

Form IT-648 is designed to handle both direct claims and “flow-through” claims. Because many life sciences startups are organized as LLCs (treated as partnerships) or S-corporations for tax purposes, the credit often flows from the entity to the individual owners.

Schedule A: Direct Claims

This section is completed by individuals (including sole proprietors), partnerships, or estates and trusts that earned the credit directly by receiving a certificate from ESD.

• Line 1: The taxpayer enters the total amount of credit listed on their ESD certificate. This amount must not exceed the $500,000 annual entity-level cap.
• Documentation: A separate Form IT-648 must be filed for each certificate of tax credit issued, and a copy of the certificate must be attached to the return.

Schedule B: Pass-Through Credits

This schedule is utilized by partners in a partnership, shareholders of a New York S-corporation, or beneficiaries of an estate or trust.

• Identification: The taxpayer must provide the name, EIN, and the share of the credit passed through from the entity.
• S-Corporation Nuance: While an S-corporation itself files Form CT-648, its individual shareholders claim their share of the credit on Form IT-648 using the information provided by the corporation.

Schedule C: Fiduciary Allocations

Estates and trusts that divide the credit between the fiduciary and the beneficiaries use Schedule C. The division must be based on each beneficiary’s proportionate share of the income of the estate or trust. This ensures that the tax benefit is distributed in alignment with the economic interests of the parties involved.

Schedule D: Final Calculation

This schedule aggregates the credits from Schedules A and B to arrive at a total credit amount. For Article 22 filers, this total is transferred to the main tax return (e.g., Form IT-201-ATT or IT-203-ATT for individuals, or Form IT-204 for partnerships).

Comparing Life Sciences R&D Credit vs. Excelsior Jobs Program

One of the most frequent questions businesses face is whether to apply for the Life Sciences R&D Tax Credit or the broader Excelsior Jobs Program (EJP). Revenue office guidance allows for some flexibility, but explicitly prohibits using the same expenses for multiple credits.

The Excelsior R&D Component

The Excelsior Jobs Program offers an R&D tax credit that is calculated differently than the Life Sciences R&D credit. Under EJP, the credit is equal to 50% of the portion of the Federal R&D credit that relates to expenditures in New York, capped at 6% of the state research expenditures. For “green” projects, this cap increases to 8%.

Feature	Life Sciences R&D Credit	Excelsior R&D Credit
Duration	3 Consecutive Years	Up to 10 Years
Calculation Method	Flat % of Total NY QREs	% of Federal Credit / Capped % of QREs
In-House Focus	High (Excludes Contracts)	Moderate (Follows Federal)
Benefit Level	15-20% Rate	Max 6-8% of QREs
Entity Requirement	Must be “New Business”	Broad (Strategic Industries)

Strategic Selection

For a true startup with fewer than 10 employees, the 20% flat rate of the Life Sciences R&D credit is significantly more generous than the EJP R&D credit. However, the Life Sciences credit is capped at three years. A firm that anticipates a long research phase and intends to hire a large number of employees (meeting the EJP job growth thresholds) might find the 10-year EJP benefit period more attractive in the long run. Additionally, firms that rely heavily on contract research—which is allowed under EJP but excluded under the Life Sciences credit—may be forced toward the EJP route by default.

Economic Impact and Program Statistics

The efficacy of the Life Sciences R&D Tax Credit is tracked through annual reports issued by Empire State Development. These reports provide a quantitative look at how the program is fulfilling its legislative mandate.

Growth of the Life Science Ecosystem

According to the 2023 and 2024 annual reports, the initiative has driven significant economic activity in the state. Between 2017 and 2022, New York saw a 27.1% growth in the number of life science companies and an 18.5% increase in the number of life science jobs. This job growth rate is notably higher than both the state’s general private sector and the national private sector average.

Key Indicator (ESD 2024 Report)	Result
New Companies Formed/Retained	32
New Jobs Created	613
Patents Filed or Granted	181
Total ESD Grant Commitments	$221.53 Million
Life Science R&D Credits Funded	$18.2 Million (cumulative)

Regional Concentration

The impact is heavily concentrated in certain regions, particularly New York City’s biotech corridor. Since 2018, over $50 million in life sciences incentives (including tax credits and grants) has been allocated to firms in the NYC area. The expansion of lab space—now exceeding 3.1 million square feet in New York City—serves as a physical manifestation of the industry’s growth fueled by these incentives.

Case Study: BioGenix Research LLC

To illustrate the application of Form IT-648 and the underlying laws, we can look at a representative example of a biotech startup’s journey through the New York state tax system.

Background and Setup

BioGenix Research LLC was founded in early 2023 by two scientists in Buffalo, NY. The entity is a multi-member LLC treated as a partnership for tax purposes. It is focused on bioinformatics and genomics for cancer diagnostic tools. At its inception, BioGenix has 6 full-time employees, which places it in the 20% credit rate tier.

Year 1 Expenditures

In its first year of operation, BioGenix incurs the following expenses:

• Wages for Researchers: $800,000 (all conducted in Buffalo).
• Wages for Admin/Sales: $100,000.
• Laboratory Supplies: $150,000.
• Cloud Data Storage (AWS): $50,000.
• Contract Research (third-party lab): $200,000.

Step 1: Identifying NY QREs

Under New York Law Section 43 and TSB-M-17(1)C guidance, BioGenix must filter these costs:

• The admin/sales wages are excluded as they are not “qualified services”.
• The contract research ($200,000) is strictly excluded.
• The remaining researcher wages, supplies, and computer fees total $1,000,000 ($800k + $150k + $50k).

Step 2: ESD Certification and Form IT-648 Filing

BioGenix applies to ESD and is certified. The credit is calculated at 20% of the $1,000,000 QREs, resulting in a $200,000 credit. ESD issues a certificate for this amount.

• BioGenix (the partnership) files Form IT-204 and attaches Form IT-648.
• In Schedule A of Form IT-648, the partnership enters the $200,000 and the certificate number.
• The credit is then divided between the two founding partners (50% each).
• Each partner receives a Schedule K-1 from BioGenix showing a $100,000 share of the credit.

Step 3: Individual Partner Claim

Partner A files their personal New York income tax return (Form IT-201).

• They attach their own Form IT-648.
• They complete Schedule B, listing BioGenix Research LLC, its EIN, and the $100,000 credit share.
• In Schedule D, they aggregate this and transfer the $100,000 to Form IT-201-ATT, line 12.
• If Partner A only owes $15,000 in state income tax, the Department of Taxation and Finance will issue them a refund check for $85,000 ($100,000 credit – $15,000 tax due).

Compliance, Audits, and Risk Management

Given the refundable nature of the credit and the high dollar amounts involved, the New York State Department of Taxation and Finance places significant emphasis on audit and compliance. Businesses must be proactive in their documentation to defend their claims on Form IT-648.

Documentation Best Practices

Revenue office guidance and industry standards suggest a “triangle audit” approach for verifying R&D claims. This involves connecting three distinct data sets to prove the validity of a claim.

1. Financial Records: General ledgers, invoices, and payroll registers that prove the money was spent and the services/supplies were obtained.
2. Human Resources Records: W-2s, employment contracts, and specifically, contemporaneous timesheets that show the exact allocation of hours to qualified research projects.
3. Project/Technical Records: Lab notebooks, meeting minutes, project plans, and test results that prove the work performed meets the “four-part test” and constitutes a process of experimentation.

Common Pitfalls and Denial Triggers

Taxpayers often face challenges during the audit process due to preventable errors.

• Relying on Estimates: The DTF and the Tax Court consistently reject management estimates or “guesses” about how much time employees spent on research. Only contemporaneous records (records made at the time of the work) are considered sufficient evidence.
• Inclusion of Post-Production Costs: Research ends once a product reaches commercial viability. Many firms incorrectly try to claim costs for quality control, routine testing, or marketing research, all of which are specifically excluded under IRC Section 41 and state guidance.
• Failure to Track “Nexus”: Every expense must be linked to a specific research activity. “Broad categories” or “lump sum” claims are high-risk triggers for an audit.
• The 80% Rule (Substantially All): If less than 80% of an employee’s time is spent on qualified research, the company can only claim the actual percentage. If 80% or more is spent, the company can claim 100% of the wages. Many firms misapply this rule by claiming 100% of all staff wages regardless of their actual research involvement.

Final Thoughts: Strategic Outlook for New York Life Sciences

The introduction of Form IT-648 and the corresponding Life Sciences R&D Tax Credit has fundamentally altered the financial landscape for biotechnology and medical device startups in New York State. By providing a generous, refundable credit that rewards internal hiring and localized research, the state has created a potent incentive for innovation. However, the program’s complexity—spanning from the initial “new business” certification with Empire State Development to the detailed flow-through mechanics on the personal income tax return—requires a sophisticated approach to tax planning.

For the modern life sciences firm, the R&D tax credit is no longer just a tax filing; it is a critical component of the company’s capital strategy. As the state continues to refine its guidance and potentially expands the $10 million annual cap to meet growing demand, businesses that master the nuances of Form IT-648 will be best positioned to thrive in New York’s rapidly expanding scientific ecosystem. The integration of rigorous technical documentation with precise financial reporting is the only way to ensure that the vision of the Life Science Initiative—turning New York into a global leader in biomedical breakthroughs—becomes a sustainable reality for individual entrepreneurs and established researchers alike.